LivaNova PLC (LIVN)

Investment Committee Summary

Investment Thesis

LivaNova is a medical device company that designs, develops, manufactures and sells therapeutic solutions globally. The economics are those of a device franchise: revenue follows procedure volumes and the installed base, while hospital capital budgets set the pace at which new equipment is adopted and the product-innovation cycle sets whether the franchise grows or matures. An operating margin near 18% and net cash of ~$0.2B describe a company with room to fund development but without the balance sheet of a large-cap consolidator. At $80.70 on 9 September 2026 the shares sit at roughly 19 times forward earnings and are fairly valued against the triangulated fair value (-4%), with the probability-weighted expected value at $78.85 — the market is paying for the base case and very little of the growth case. The decisive variable is penetration: whether an existing therapy can reach a materially wider eligible patient population is what separates the base scenario from the growth scenario, and without it the shares are simply a market-multiple device name. The most damaging risk is reimbursement, because a payer decision re-prices the entire installed base at once and the company has no control over it.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($80.70) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

Devices are hostage to two counterparties the company cannot negotiate with: payers and hospital procurement. A reimbursement reset lowers the realised price per procedure without lowering the cost of the field force, the regulatory burden or the development spend needed to keep the therapy competitive, so the 18% margin gives back proportionally more than the price cut. Competition compounds it, because a rival therapy or a substitution effect that shrinks the eligible procedure pool takes volume at the same time. The multiple is the third leg: a device name held near 19 times earnings on an assumption of durable procedure growth trades materially lower the moment that growth is questioned, and the three effects arrive together rather than in sequence. That is the structural scenario in the model, and its target sits below the 52-week low — a long way down for a stock trading far above that low.

Key Debate

P/E Multiple explains 55% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

What the Market Is Pricing In

At the current price, the market pays 18.5× consensus forward EPS, vs the house DCF terminal 16.0×, and a peer median 16.1×. The house DCF sits 2% below spot, so the market is pricing in more than the house case — roughly 0.3pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily multiple-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($34.69) to a 'Bull — Re-Rate' bull case ($140); the probability-weighted blend (PWEV $78.85) is -2% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 2.6% of revenue; free cash flow net of SBC is $0.14B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $34.69). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Hospital-Capex / Utilization Recession (17%, $58.92). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising.
• Base — Procedure Volume + Innovation (35%, $81.83). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns.
• Growth — New-Product Cycle / Penetration (20%, $110). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate (8%, $140). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $70.36 and 37% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (55% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 8.5%, 16.0x terminal FCF multiple → $79.13. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $81.40; the peer-median forward P/E is 16.1x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 14% of the median — tight (the methods corroborate one another).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 19.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 16.9× (simple median 16.1×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $41.02–$85.27, centre $59.10 (-27% vs spot); spot sits at the 90th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate): $140.

Company Overview & Business Model

LivaNova PLC — HEALTHCARE · MEDICAL DEVICES. LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.

How it makes money.

Edge. Narrow moat — inferred from a 18% operating margin and the medical devices & equipment business model. Some pricing power / share stability; terminal multiple near the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Devices Tools

This name sits in the Health Care — Devices Tools cluster as a medical devices & equipment name. procedure volumes + product-innovation cycle + hospital capital spending. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: ILMN (Life-Science tools, services & software) · MEDP (Life-Science tools, services & software) · PEN (medical devices & equipment) · GMED (medical devices & equipment) · BRKR (medical devices & equipment) · BIO (Life-Science tools, services & software) · AVTR (Life-Science tools, services & software) · LNTH (medical devices & equipment) · LIVN (medical devices & equipment) · NVST (medical devices & equipment) · DOCS (Life-Science tools, services & software) · HAE (medical devices & equipment) · XRAY (medical devices & equipment)

Mapping note: name-level 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) + 'Hospital-Capex / Utilization Recession' (17%) map to cluster Reimbursement / Funding / Utilization Reset (37%); name-level 'Growth — New-Product Cycle / Penetration' (20%) + 'Bull — Re-Rate' (8%) map to cluster Upside — Innovation / Recovery Re-Rate (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Reimbursement / Funding / Utilization Reset — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Devices Tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.52 vs analyst floor +0.05 → delta +0.47 (n=23 mgmt / 12 Q&A; 63rd pctile across the S&P book, z +0.4).

Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.

News (last 365d, 274 articles): avg ticker sentiment +0.29 (bullish 43% / bearish 1%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Forecast Track Record

• EPS surprise: beat 100% of the last 8 quarters; average surprise +13.5%.
• Prior-forecast backtest (19 snapshots, 2026-07-21→2026-09-03): directional hit-rate 74%; mean predicted -1.1% vs realised +1.2%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

4 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 5 evaluable (1 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 1.45 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 80.7 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $80.70; 52-week range $41.02–$85.27; engine rating HOLD; house target $78.85 (-2%). (source: Alpha Vantage 2026-09-08, 9 September 2026)
• INFERENCE: Triangulated FV $77.28 (-4% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits above the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

65.1/100 (confidence band 55.9–74.3), 76th percentile of 893 covered names (as of 2026-09-08). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 63.2 → 63.1 → 62.9 → 62.8 → 64.6 → 64.9 → 64.5 → 64.7.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $78.85.

Flagged for review: internal coherence (authored mass vs Monte Carlo). A flag marks a disagreement worth understanding — it does not imply either side is wrong.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.35, vs QQQ +0.29 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Covered Call. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• range-bound with fair premium — harvest income against a holding
• Direction neutral from the overlay conviction/rating (read-only input).
• IV/RV at the 34th percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 21st percentile of its own month-end history (decile 3). The two measures disagree here — vol is high for this name by its own history while its options are not unusually rich against its realised vol. Where they diverge, the cross-sectional measure is the one acting.

IV term structure (flat, slope -1.0pp): 38-DTE 39% · 101-DTE 40% · 220-DTE 38%

Economics copied verbatim from the options overlay (priced from the listed chain (EOD marks)); the selector does not re-price.

Alternatives: Cash-Secured Put. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the HOLD equity view. Chain as of 2026-09-08 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 38.6% (moderate regime) · expected move ±9.6% (2026-10-16) · put/call OI 0.47 · ATM Δ 0.56 / Θ -0.06 / ν 0.10. Direction: NEUTRAL (implied return -4.2% to triangulated fair value $77.28).

Covered Call (if held) (Income / neutral) — Short 87.5 C · 2026-10-16 · premium $1.85 · yield 2.3% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Protective Collar (if held) (Hedge) — Long 72.5 P / Short 90 C · 2027-04-16 · net $1.12 · floor -10.0% · cap +12.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -2% vs spot
• Monte Carlo median implies -13% vs spot
• DCF fair value implies -2% vs spot
• Bear case (Structural — Reimbursement / Competition / GLP-1 Procedure Hit) downside is -57% vs spot
• Net: the valuation anchor itself sits 4.2% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 8.5% · Σ PV(FCF) $1B + PV(terminal) $3B = EV $4B; + net cash $0.2B → equity $4B ÷ diluted shares $0.06B = $79.13/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $82.95/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 15% vs WACC 8.5% → above WACC — the build is value-creative.

Peer set

Implied prices at the peer medians: EV/Rev → $81.40 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (23.0); Terminal × ±15% (17.0); Revenue CAGR ±3pp (17.0); Capex intensity ±15% (7.0); WACC ±1pp (6.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 8.5%, terminal multiple 16×, FY+5 revenue $2B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.